Hedgehog Pathway Inhibitors Market Size Trends Insights | Japan | China | 2022

Hedgehog pathway inhibitors Market Outlook:

Hedgehog pathway inhibitors are relatively a new class of therapeutic agents that target the proteins involved in the regulation of the hedgehog pathway.

The global hedgehog pathway inhibitors market was worth USD YY% million in 2021 and is estimated to reach USD YY% million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

The hedgehog pathway inhibitors market growth is driven by the rising prevalence of cancer, hereditary factors, new product launches, rising demand for painless or minimally invasive treatment, and increased resistance to existing therapies. The rise in the risk factors associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML) is projected to fuel the global hedgehog pathway inhibitors market.

The risk factors associated with developing basal cell carcinoma and acute myeloid leukemia include chronic infections, history of skin cancer, exposure to certain chemicals, skin inflammations, smoking, and exposure to UV rays. These risk factors raise the prevalence and incidence of basal cell carcinoma and acute myeloid leukemia. North America region is predicted to dominate the global hedgehog pathway inhibitors market throughout the forecast period.

Browse Full Report @ https://www.datamintelligence.com/research-report/hedgehog-pathway-inhibitors-market

Hedgehog pathway inhibitors Market Growth Dynamics:

The rising prevalence of cancer is boosting the Hedgehog pathway inhibitors market. For instance, according to the American Cancer Society, approximately 1.9 million new cancer cases were registered for 2021 in the US. Nearly 9,500 people in the US are a target of skin cancer or basal cell carcinoma.

Estimation says that non-melanoma carcinoma, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million globally per year. The number of newly diagnosed invasive melanoma cases in the U.S. is predicted to have increased by more than 40% between 2009 and 2019. According to projections, there will be 196,060 new cases of melanoma diagnosed in 2020 (95,710 noninvasive and 100,350 invasive), and there will be 7,850 deaths from the condition.

According to the AIM at Melanoma Foundation, in 2022 in the United States, it was estimated that there will be 197,700 cases of melanoma diagnosed. Of those, 97,920 cases will be noninvasive (in situ) and 99,780 cases will be invasive.

According to the American Brain Tumor Association, approximately 25% of patients in the US are suffering from medulloblastoma due to the uncontrolled Sonic Hedgehog (SHH) pathway. Individuals with medulloblastoma showed a high cholesterol level when the combination of statin (simvastatin) and Hedgehog pathway inhibitor (vismodegib) was administered to the cohort. The combination therapeutics produces synergistic activity of the inhibitors.

Hedgehog pathway inhibitors Market Segmentation:

By Product Type:
• Vismodegib
• Glasdegib
• Sonidegib
• Itraconazole
• Oxysterol
• Saridegib

By Pathway Type:
• Canonical Hedgehog Signaling
• Non-Canonical Hedgehog Signaling

The basal cell carcinoma segment is estimated to grow at a CAGR of YY% during the forecast period (2022-2029) to reach a market value of USD YY million by 2029. The basal cells of the lower epidermis exhibit uncontrolled and abnormal growth in basal cell carcinoma (BCC). It doesn't spread to body parts, but in a very rare circumstance, it may metastasize and be shown to be life-threatening, even though it may penetrate deeply into the skin and bones.

It is brought on by excessive UV exposure, and the lesions that develop during BCC resemble open sores, red patches, or occasionally bumps. For the treatment of basal cell carcinoma, a variety of options are available, including surgery, medications, and other methods.

Over the forecast period, it is anticipated that the global basal cell carcinoma market will grow due to the rising prevalence of skin cancers. For instance, basal cell carcinoma (BCC) is thought to be the most prevalent type of skin cancer, according to the Skin Cancer Foundation in 2021.
Additionally, 3.6 million BCC cases are thought to be diagnosed annually in the United States.
The market's leading players are concentrating on getting their products approved for the treatment of BCC, which is anticipated to propel the growth of the basal cell carcinoma segment over the forecast period.

For instance, the European Commission (EC) approved Regeneron's PD-1 inhibitor Libtayo (cemiplimab) to treat adults with metastatic basal cell carcinoma (BCC) or locally advanced who are intolerant or have progressed on to a hedgehog pathway inhibitor in June 2021, according to Sanofi, a French multinational pharmaceutical corporation with headquarters in Paris, France (HHI).

Download Sample Report @ https://www.datamintelligence.com/download-sample/hedgehog-pathway-inhibitors-market

Hedgehog pathway inhibitors Market Regional Insights:

By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

North America hedgehog pathway inhibitors market is estimated to grow at a CAGR of YY% during the forecast period (2022-2029) to reach a market value of USD YY million by 2029. The United States dominated the North America hedgehog pathway inhibitors market with a share of YY% in the year 2021.

High prevalence of basal cell carcinoma & acute myeloid leukemia is anticipated to drive the hedgehog pathway inhibitors market in the region during the forecast period. According to the American Cancer Society (ACS), an estimated 5.4 million people are diagnosed with squamous and basal cell skin cancer globally each year.

Approximately 90% of non-melanoma skin cancers are linked to sun exposure, according to data from the Skin Cancer Foundation updated in May 2022. Basal cell carcinoma (BCC) is the most common type of skin cancer, according to estimates from the Skin Cancer Foundation. According to the same source as above, the annual cost of treating skin cancers in the United States is estimated to be USD 8.1 billion, of which USD 3.3 billion is spent on melanoma and USD 4.8 billion is spent on non-melanoma skin cancers.

Moreover, increase in number of new product approvals is expected to drive the market growth positively. For instance, Pellepharm has introduced Saridegib (Patidegib), a hedgehog pathway inhibitor. It is used as a topical treatment measure for patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs).

Hedgehog pathway inhibitors Market Competitive Insights:

Some of the key players which are contributing to the growth of the market include Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, and Bristol-Myers Squibb Company, Novartis. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Mayne Pharma Group Limited took control of SUBA-itraconazole BCCNS program from HedgePath Pharmaceuticals, Inc.

Sai Kiran
DataM Intelligence 4Market Research LLP
+1 877-441-4866
info@datamintelligence.com

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

We monitor and analyze the market by dissecting various market influencers, competitive intensity, innovations, trends, and emerging products. This aids us in providing a detailed scenario of the present and future of the market.

This release was published on openPR.